CD45+ immune cells are classified into 37 cell subsets (C01–37) and the differences in these subsets between the improved and non-improved groups, and before and after ALSS therapy, are shown in Fig. 1B. The classification of all CD45+ immune cells, including the expression of key marker molecules, is provided in Table S3. This evidence concerns the gene PTPRC and Alstrom syndrome.